Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer. | J Clin Oncol;22(19): 3950-7, 2004 Oct 01. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Phase III double-blind placebo-controlled study of farnesyl transferase inhibitor R115777 in patients with refractory advanced colorectal cancer.

Rao, S; Cunningham, D; de Gramont, A; Scheithauer, W; Smakal, M; Humblet, Y; Kourteva, G; Iveson, T; Andre, T; Dostalova, J; Illes, A; Belly, R; Perez-Ruixo, J J; Park, Y C; Palmer, P A.

Affiliation

Rao S; Royal Marsden Hospital, Downs Rd, Sutton, Surrey SM2 5PT, United Kingdom.

J Clin Oncol ; 22(19): 3950-7, 2004 Oct 01.

Article in En | MEDLINE | ID: mdl-15459217

Subject(s)

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Quinolones / Antineoplastic Agents Type of study: Clinical_trials Aspects: Patient_preference Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2004 Document type: Article Affiliation country:

Search on Google

Collection: 01-internacional Database: MEDLINE Main subject: Colorectal Neoplasms / Quinolones / Antineoplastic Agents Type of study: Clinical_trials Aspects: Patient_preference Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: J Clin Oncol Year: 2004 Document type: Article Affiliation country: